Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860867 | 1.00 | DPP4 (0.52) | DPP4DPP7DPP8DPP9REN | |
| SCHEMBL5503748 | 0.86 | DPP4 (0.39) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL5505794 | 0.80 | REN (0.52) | REN | |
| SCHEMBL1866281 | 0.80 | REN (0.52) | REN | |
| SCHEMBL5503829 | 0.80 | REN (0.52) | REN | |
| SCHEMBL5509831 | 0.80 | REN (0.52) | REN | |
| SCHEMBL1865703 | 0.80 | REN (0.52) | REN | |
| SCHEMBL14987883 | 0.76 | CTSS (0.55) | REN | |
| SCHEMBL3602438 | 0.76 | CTSS (0.55) | REN | |
| SCHEMBL5509283 | 0.73 | REN (0.47) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | DPP4 14/4885DPP7 5/4885DPP8 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.